- Home
- CLLS vs MPA Comparison
CLLS vs MPA Comparison
Compare CLLS & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- MPA
- Stock Information
- Founded
- CLLS 1999
- MPA 1992
- Country
- CLLS France
- MPA United States
- Employees
- CLLS 216
- MPA N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- MPA Finance Companies
- Sector
- CLLS Health Care
- MPA Finance
- Exchange
- CLLS Nasdaq
- MPA Nasdaq
- Market Cap
- CLLS 148.1M
- MPA 159.3M
- IPO Year
- CLLS 2007
- MPA N/A
- Fundamental
- Price
- CLLS $1.48
- MPA $11.94
- Analyst Decision
- CLLS Buy
- MPA
- Analyst Count
- CLLS 3
- MPA 0
- Target Price
- CLLS $7.00
- MPA N/A
- AVG Volume (30 Days)
- CLLS 235.1K
- MPA 25.2K
- Earning Date
- CLLS 11-04-2024
- MPA 01-01-0001
- Dividend Yield
- CLLS N/A
- MPA 3.83%
- EPS Growth
- CLLS N/A
- MPA N/A
- EPS
- CLLS N/A
- MPA N/A
- Revenue
- CLLS $36,042,000.00
- MPA N/A
- Revenue This Year
- CLLS $387.77
- MPA N/A
- Revenue Next Year
- CLLS $11.14
- MPA N/A
- P/E Ratio
- CLLS N/A
- MPA N/A
- Revenue Growth
- CLLS 46.96
- MPA N/A
- 52 Week Low
- CLLS $1.41
- MPA $9.87
- 52 Week High
- CLLS $3.38
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- CLLS 38.66
- MPA 53.46
- Support Level
- CLLS $1.65
- MPA $11.71
- Resistance Level
- CLLS $2.23
- MPA $11.99
- Average True Range (ATR)
- CLLS 0.18
- MPA 0.16
- MACD
- CLLS -0.03
- MPA 0.04
- Stochastic Oscillator
- CLLS 8.54
- MPA 91.30
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.